Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Asymchem Laboratories (Tianjin) Co., Ltd.
凱萊英醫藥集團(天津)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6821)

COMPLETION OF THE REPURCHASE AND CANCELLATION OF PART OF THE RESTRICTED A SHARES GRANTED UNDER THE 2025 A SHARE SCHEME

References are made to (i) the circulars of Asymchem Laboratories (Tianjin) Co., Ltd. (the "**Company**") dated 18 March 2025 and 26 March 2026 (collectively, the "**Circulars**"), in relation to, among others, the 2025 A share restricted share incentive scheme of the Company (the "**2025 A Share Scheme**"), and (ii) the announcements of the **Company** dated 24 January 2025, 3 April 2025, 29 September 2025, 19 December 2025 and 13 March 2026 (collectively, the "**Relevant Announcements**"), in relation to, among other things, the repurchase and cancellation of part of the Restricted A Shares granted under the 2025 A Share Scheme. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circulars.

As of the date of this announcement, the repurchase and cancellation of the 94,000 Restricted A Shares in total under (i) the initial grant of the 2025 A Share Scheme held by 11 incentive participants who have resigned and (ii) the reserved grant of the 2025 A Share Scheme held by two incentive participants who have resigned have been completed. The issued share capital of the Company has been reduced from 360,874,970 Shares (comprising 333,040,460 A Shares and 27,834,510 H Shares) to 360,780,970 Shares (comprising 332,946,460 A Shares and 27,834,510 H Shares). The changes in the issued share capital of the Company are further detailed below (the "**Change**"):

Class of Shares	**Before the Change (Share)**	**Percentage of total issued share capital (%)**	**Change (Share)**	**After the Change (Share)**	**Percentage of total issued share capital (%)**
A Shares	333,040,460	92.29	(94,000)	332,946,460	92.28
H Shares	27,834,510	7.71	–	27,834,510	7.72
Total	**360,874,970**	**100.00**	**(94,000)**	**360,780,970**	**100.00**

Such repurchase and cancellation will not result in any change of the controlling shareholder of the Company. The Company's shareholding structure will remain in compliance with relevant requirements under the listing rules of the Shenzhen Stock Exchange and The Stock Exchange of Hong Kong Limited.

IMPACT OF THE REPURCHASE AND CANCELLATION ON THE OPERATING RESULTS OF THE COMPANY

Such repurchase and cancellation will not have any material impact on the operating results and financial conditions of the Company.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
Chairperson of the Board, Executive Director and Chief Executive Officer

Tianjin, the PRC, 12 June 2026

As of the date of this announcement, the Board of the Company comprises Dr. Hao Hong as the Chairperson of the Board and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Xie Weikai as independent non-executive Directors.